Premium
Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial
Author(s) -
Reiffers J.,
Gaspard M. H.,
Maraninchi D.,
Michallet M.,
Marit G.,
Stoppa A. M.,
Corront B.,
David B.,
Gastaut J. A.,
Sotto J. J.,
Broustet A.,
Carcassonne Y.,
HOLLARD D.
Publication year - 1989
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1989.tb07652.x
Subject(s) - medicine , myeloid leukaemia , chemotherapy , bone marrow transplantation , bone marrow , transplantation , myeloid , myeloid leukemia , oncology , chronic myeloid leukaemia , hematology
Summary. Eighty‐five adult patients under the age of 50 years with acute myeloid leukaemia (AML) were entered into a prospective controlled study conducted to compare the effectiveness of allogeneic or autologous bone marrow transplantation and intensive chemotherapy for patients in first complete remission. Sixty‐one patients (72%) achieved complete remission then received a consolidation treatment. After consolidation, 58 patients who were still in remission were assigned to three different therapeutic modalities. Fifty‐two patients were evaluable: 20 patients who had an HLA‐identical sibling donor underwent allogeneic bone marrow transplantation within 3 months after achievment of complete remission; the other 32 patients were randomized to receive autologous bone marrow transplantation or intensive sequential chemotherapy. The actuarial risk of relapse at 3 years was 18% for the allogeneic patients, 50% for the autologous patients and 83% in the chemotherapy group. The difference was highly significant ( P <0.0002). The disease‐free survival was respectively 66% (95% confidence interval 41–85%), 41% (95% confidence interval 16–66%) and 16% (95% confidence interval 0–31%) ( P <0.004). We conclude that allogeneic bone marrow transplantation is presently the best therapeutic approach for patients with AML in first complete remission.